Do you want to read an article? Please log in or register.
Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles
Asthma
Related content
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
Asthma
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry
J Asthma Allergy
Le TT, Price DB, Erhard C, Cook B, Quinton A, Katial R, Christoff GC, Perez-de-Llano L, Altraja A, Bergeron C, Bourdin A, Koh MS, Lehtimäki L, Mahboub B, Papadopoulos NG, Pfeffer P, Rhee CK, Carter V, Martin N, Tran TN, EVEREST Study Working Group
doi: 10.2147/JAA.S468068
RECOMMENDED
Asthma
Asthma Control and Associated Factors Among Children with Current Asthma - Findings from the 2019 Child Behavioral Risk Factor Surveillance System - Asthma Call-Back Survey
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Asthma Allergy
Habte BM, Beyene KA, Patel SA, Fenta TG, Fitzpatrick AM
doi: 10.2147/JAA.S465550
AsthmaRespiratory Tract Infection
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Respir Med
Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C
doi: 10.1016/j.rmed.2025.108203
RECOMMENDED
Asthma
A Real-world Study on Tezepelumab Effectiveness in Severe Asthma Focusing on Small Airway Dysfunction
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Menzella F, Cottini M, Lombardi C, Senna G, Chan R, Bosi A, Bortoli M, Tonin S, Corsi L, Rastelli A, Marchi MR
doi: 10.1016/j.rmed.2025.108054
RECOMMENDED
Asthma
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE
doi: 10.1183/13993003.00316-2024
Asthma
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study
Adv Ther
Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B
doi: 10.1007/s12325-025-03231-6
RECOMMENDED
Asthma
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Zein JG, Zounemat-Kerman N, Adcock IM, Hu B, Attaway A, Castro M, Dahlén SE, Denlinger LC, Erzurum SC, Fahy JV, Gaston B, Hastie AT, Israel E, Jarjour NN, Levy BD, Mauger DT, Moore W, Peters MC, Sumino K, Townsend E, Woodruff P, Ortega VE, Wenzel SE, Meyers DA, Chung KF, Bleecker ER, Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) Consortium and the the US National Heart, Lung, and Blood Institute Severe Asthma Research Program (SARP III)
doi: 10.1016/S2213-2600(24)00250-9
RECOMMENDED
Asthma
Real-World Safety Profile of Biologic Drugs for Severe Uncontrolled Asthma: A Descriptive Analysis from the Spanish Pharmacovigilance Database
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Boada-Fernández-Del-Campo C, García-Sánchez-Colomer M, Fernández-Quintana E, Poza-Guedes P, Rolingson-Landaeta JL, Sánchez-Machín I, González-Pérez R
doi: 10.3390/jcm13144192